Abstract
The essential features of persistent severe asthma include structural changes in the airway wall (remodelling). It is not known whether these are the sequelae of chronic inflammation or indeed its initiators. Several transcription factors have been implicated in the inflammatory process in asthma, including the glucocorticoid receptor (GR), NFκB, Activator Protein-1 (AP-1), Nuclear Factor of Activated T-cells (NF-AT), cyclic AMP Response Element Binding Protein and more recently, the CCAAT/Enhancer Binding Protein (C/EBP), Peroxisome Proliferator-activated Receptor (PPAR) and the bZIP transcription factor, Nrf2. Could a pathological de-regulation of one of these transcription factors explain the broad spectrum of asthma pathology and can their modulation lead to better symptom control? Although some of the transcription factors seem to be valid targets (NFkB, Nrf2 or STAT6) or tools (PPARγ, -α and C/EBP-α) for new therapeutic approaches, since many transcription factors play a central role in tissue and organ homeostasis, a longterm general suppression or overexpression, would cause severe side effects in other organs. Cell type specific application of decoy or antisense oligonucleotides for NFκB, Nrf2 or STAT6, or specific agonists for PPARγ and -α may help to control the inflammatory response in lung epithelial cells and infiltrated immune cells, but additional, unwanted, effects on other resident cells of the lung cannot be excluded and a beneficial effect over known antiasthma drugs has first to be proven. In order to progress with such novel therapeutic strategies, the only option seems to be to link transcription factor inhibitors/activators to a cell type specific delivery system.
Keywords: asthma, airway remodelling, airway smooth muscle, transcription factors, asthma therapy
Current Drug Targets
Title: Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?
Volume: 7 Issue: 5
Author(s): M. Roth and J. L. Black
Affiliation:
Keywords: asthma, airway remodelling, airway smooth muscle, transcription factors, asthma therapy
Abstract: The essential features of persistent severe asthma include structural changes in the airway wall (remodelling). It is not known whether these are the sequelae of chronic inflammation or indeed its initiators. Several transcription factors have been implicated in the inflammatory process in asthma, including the glucocorticoid receptor (GR), NFκB, Activator Protein-1 (AP-1), Nuclear Factor of Activated T-cells (NF-AT), cyclic AMP Response Element Binding Protein and more recently, the CCAAT/Enhancer Binding Protein (C/EBP), Peroxisome Proliferator-activated Receptor (PPAR) and the bZIP transcription factor, Nrf2. Could a pathological de-regulation of one of these transcription factors explain the broad spectrum of asthma pathology and can their modulation lead to better symptom control? Although some of the transcription factors seem to be valid targets (NFkB, Nrf2 or STAT6) or tools (PPARγ, -α and C/EBP-α) for new therapeutic approaches, since many transcription factors play a central role in tissue and organ homeostasis, a longterm general suppression or overexpression, would cause severe side effects in other organs. Cell type specific application of decoy or antisense oligonucleotides for NFκB, Nrf2 or STAT6, or specific agonists for PPARγ and -α may help to control the inflammatory response in lung epithelial cells and infiltrated immune cells, but additional, unwanted, effects on other resident cells of the lung cannot be excluded and a beneficial effect over known antiasthma drugs has first to be proven. In order to progress with such novel therapeutic strategies, the only option seems to be to link transcription factor inhibitors/activators to a cell type specific delivery system.
Export Options
About this article
Cite this article as:
Roth M. and Black L. J., Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?, Current Drug Targets 2006; 7 (5) . https://dx.doi.org/10.2174/138945006776818638
DOI https://dx.doi.org/10.2174/138945006776818638 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Current Medicinal Chemistry Recent Patents on Influenza Vaccines
Recent Patents on Biotechnology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Identification and Characterization of β-Adrenoceptor Agonists and Antagonists
Current Topics in Medicinal Chemistry Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models
Recent Patents on Inflammation & Allergy Drug Discovery Pseudomonas aeruginosa -Eukaryotic Cell Crosstalk: Mediators, Mechanisms and Implications for the Antimicrobial Therapy
Current Organic Chemistry Clinical Analysis Methods of Voice Disorders
Current Bioinformatics The Role of Bacterial DNA in Inflammatory and Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Patent Annotations
Recent Patents on Inflammation & Allergy Drug Discovery Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective
Current Pharmaceutical Design Cytokine Antibody Arrays: A Promising Tool to Identify Molecular Targets for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Exhaled Breath Condensate in Asthma: From Bench to Bedside
Current Medicinal Chemistry Therapeutical Approach to Arterial Hypertension - Current State of the Art
Current Medicinal Chemistry Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery
Current Gene Therapy Antimicrobial Cyanopeptide Action on Bacterial Cells Observed with Atomic Force Microscopy
Current Nanoscience Recent Applications of Triazolopyrimidine-Based Bioactive Compounds in Medicinal and Agrochemical Chemistry
Mini-Reviews in Medicinal Chemistry Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design